Detalles de la búsqueda
1.
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Drug Metab Dispos
; 43(9): 1360-71, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149830
2.
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Invest New Drugs
; 32(5): 825-37, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919854
3.
Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors.
Br J Pharmacol
; 176(1): 110-126, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30276808
4.
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Clin Cancer Res
; 20(14): 3763-74, 2014 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24850847
5.
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
Mol Cancer Ther
; 13(6): 1442-56, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24688048
6.
Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.
Bioorg Med Chem Lett
; 17(6): 1765-8, 2007 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17239592
Resultados
1 -
6
de 6
1
Próxima >
>>